Roche - Articles and news items

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

Roche receives FDA approval for bladder cancer biomarker assay

Industry news / 5 May 2017 / Niamh Marriott, Junior Editor

The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma…

FDA approves Roche’s high-volume immunoassay

Industry news / 4 May 2017 / Niamh Marriott, Junior Editor

Roche’s new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyser series, the cobas e 801 module, has received 510(k) clearance from the US Food and Drug Administration (FDA). As core laboratories continue to evolve to meet the growing workload demands in an increasingly challenging environment, the cobas e 801 module offers greater […]

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

Ovarian assay

FDA approves Roche’s assay to assess ovarian reserve

Industry news / 10 January 2017 / Niamh Marriott, Digital Editor

The blood test produces standardised results for assessing ovarian reserve as compared with the use of vaginal ultrasound…

NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use

Industry news / 29 December 2016 / Niamh Louise Marriott, Digital Editor

Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should…

Price discount helps give green light for Roche’s breast cancer drug

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

Prothena’s Phase 1b Parkinson’s disease study showed robust antibody CNS penetration

Industry news / 11 November 2016 / Niamh Louise Marriott, Digital Content Producer

Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease…

FDA approves Roche’s immunotherapy assay to support treatment decisions in lung cancer

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) has approved Roche’s PD-L1 assay as a diagnostic to identify PD-L1 expression levels in patients considering treatment with Tecentriq (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC). The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer (UC) who may benefit from treatment […]

FDA approves Roche’s blood screening assay for donor screening

Industry news / 24 October 2016 / Niamh Louise Marriott, Digital Content Producer

The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+